T. Doležal 1; Z. Písaříková 1; P. Zemanová 1; D. Bartášková 2
Ústav farmakologie 3. lékařské fakulty UK Praha, přednosta prof. MUDr. Miloslav Kršiak, DrSc.
1; Diabetologické centrum Interní kliniky 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA
Vnitř Lék 2009; 55(4): 342-344
The analysis of direct medical care costs in the conditions of the Czech Republic has demonstrated that the average annual costs per type II diabetic patient amounts to 25,858 CZK. Thanks to its high prevalence and incidence, it represents 10% of total medical care costs. The hospital treatment of diabetic complications takes up the major share in these costs, similarly as in other advanced European countries. It is therefore evident that type II diabetes has not only health but also economic and social impacts and from this point of view, preventative and therapeutical strategies need to be evaluated.
Key words: diabetes mellitus, type II – direct costs – diabetic complications – pharmacoeconomics
1. Ettaro L, Songer TJ, Zhang P et al. Cost‑of-illness studies in diabetes mellitus. Pharmacoeconomics 2004; 22: 149–164.
2. Jönsson B, CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002; 45: S5–S12.